Metamark Genetics Partners with Definiens on Tissue-Based Cancer Diagnostics
Metamark Genetics, a privately-held oncology molecular diagnostic company, and Definiens announced a development and commercialization partnership in which Metamark will combine its proprietary multiplex protein detection platform with image analysis technology developed jointly with Definiens to deliver innovative prognostic and predictive assays for early-stage cancers.
Metamark's quantitative diagnostic approach can identify and account for small regions of molecularly aggressive cancer cells within an otherwise indolent tumor. The company is developing a portfolio of prognostic and predictive assays with the ability to address the "heterogeneous" nature of tumors not only between one patient and the next, but also within an individual patient's tumor.
Definiens has made ground-breaking achievements in the field of biomarker development based on its highly robust and scalable image analysis framework that enables scientists and clinicians to rapidly extract comprehensive biomarker and morphology expression profiles and to identify a relevant subset of descriptors by correlating them against patient outcomes.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Stanford University Licenses Ingenuity Pathways Analysis, Collaborates on Systems Biology Solutions - Stanford Genome Technology Center Will apply Ingenuity's technology to More Quickly and Comprehensively Understand the Biology Underlying Their Experimental Datasets
Spoiled oranges shine light on malignant cells - Biomedical device passes the litmus test
UT Southwestern researchers determine 3-D atomic structure of cholesterol transporter
Mount Sinai researchers develop tool to determine function of MicroRNAs
PAION agreement with Lundbeck comes into force, securing future Desmoteplase development and EUR 8 million upfront-payment
Epistem's Biomarker Division Gains GCLP Accreditation
Association for Professionals in Infection Control and Epidemiology, Inc. (APIC) - Washington, USA
Hereditary_nonpolyposis_colorectal_cancer
ClinTec’s CEO, Dr Rabinder Buttar wins the Institute of Directors, Director of the Year Award for Glasgow & West of Scotland
Rescue protein gives doomed cells a stay of 'execution'
Weill Cornell, Ithaca researchers use cotton candy to create new bloodflow routes
